Search - tctmd.com

Displaying 661 - 680 of 825

Sort: Relevancy | Date

News Industry News

New RE-VERSE AD™ Analyses Provide Additional Insights on Impact of Idarucizumab (Praxbind®) in Pradaxa® Patients with Gastrointestinal Bleeding or Needing Emergency Surgery

November 14, 2017

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

News Conference News AHA 2017

AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More

Shelley Wood

November 09, 2017

Presentation TCT 2017

Current State-of-the-Art Diabetes Medical Management and Novel Therapies in Clinical Trials

Presenter: David J. Maron, Alan C. Yeung, Michael E. Farkouh

November 01, 2017

News Daily News

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Michael O'Riordan

October 26, 2017

News Daily News

Statins and Diabetes: Causal Link Reinforced in New Analysis

Michael O'Riordan

October 25, 2017

News Daily News

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

Michael O'Riordan

October 20, 2017

News Daily News

Women, Minorities at Greater Risk for Non-Stent-Related Events After PCI

Yael L. Maxwell

October 20, 2017

News Daily News

High Blood Pressure May Raise Mitral Regurgitation Risk

Todd Neale

October 17, 2017

News Industry News

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

October 02, 2017

News Features

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

Michael O'Riordan

September 13, 2017

News Opinion Editor's Corner ESC 2017

My Takeaways From ESC 2017: That Lovin’ Feeling? Barcelona Brings It Back

Shelley Wood

September 08, 2017

News Industry News

RE-DUAL PCI™ Results Offer Favorable New Safety Data on Pradaxa®

August 28, 2017

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

Shelley Wood

August 18, 2017

News Daily News

Fibrinolytic Agents for STEMI: Meta-analysis Explores the Differences

Todd Neale

August 18, 2017

News Daily News

Air Pollution Tightly Tied to CV Disease, Chinese Study Confirms

Ashley Lyles

August 15, 2017

News Daily News

Readmissions After Acute MI Not Only Confined to the Elderly

Yael L. Maxwell

August 09, 2017

News Daily News

One in Four ICD Patients Need Reintervention Within 5 Years

Ashley Lyles

August 04, 2017

News Features

A Heart to Hold: 3-D Printers Add New Dimension to the Treatment of Structural Cardiac Disease

Yael L. Maxwell

August 02, 2017

Advertisement

New RE-VERSE AD™ Analyses Provide Additional Insights on Impact of Idarucizumab (Praxbind®) in Pradaxa® Patients with Gastrointestinal Bleeding or Needing Emergency Surgery

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More

Current State-of-the-Art Diabetes Medical Management and Novel Therapies in Clinical Trials

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Statins and Diabetes: Causal Link Reinforced in New Analysis

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

Women, Minorities at Greater Risk for Non-Stent-Related Events After PCI

High Blood Pressure May Raise Mitral Regurgitation Risk

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

My Takeaways From ESC 2017: That Lovin’ Feeling? Barcelona Brings It Back

RE-DUAL PCI™ Results Offer Favorable New Safety Data on Pradaxa®

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

Fibrinolytic Agents for STEMI: Meta-analysis Explores the Differences

Air Pollution Tightly Tied to CV Disease, Chinese Study Confirms

Readmissions After Acute MI Not Only Confined to the Elderly

One in Four ICD Patients Need Reintervention Within 5 Years

A Heart to Hold: 3-D Printers Add New Dimension to the Treatment of Structural Cardiac Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content